Skip to content

Clinical study of Ganoderma lucidum extract in the treatment of motor and non motor symptoms in patients with early PD

Clinical study of Ganoderma lucidum extract in the treatment of motor and non motor symptoms in patients with early PD

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100050538
Enrollment
Unknown
Registered
2021-08-28
Start date
2021-09-01
Completion date
Unknown
Last updated
2022-05-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson's disease

Interventions

Experimental group:Reishi Mushroom Extract Treatment
Control group:None

Sponsors

Xuanwu Hospital of Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Meet the diagnostic criteria of "clinically probable PD" for MDS primary Parkinson's disease; 2. Aged 30 to 80 years at the time of diagnosis of Parkinson's; 3. H-Y clinical grade <= 2; 4. The UPDRS ? score is between 10-30 (including 10 and 30); 5. The course of the disease does not exceed 5 years; 6. Have not received anti-Parkinsonian drugs or other treatments, or have discontinued treatment drugs for more than 2 weeks (drugs include dopamine preparations, dopa receptor agonists, COMT inhibitors, MAO inhibitors, antan, amantadine); 7. Agree to participate in this experiment, sign the informed consent form, and be willing to abide by the relevant experimental regulations, take medication on time and come to review regularly; 8. Agree to receive only experimental drug treatment in the next 1.5 years, and receive anti-Parkinsonian drug treatment as prescribed by a doctor when necessary.

Exclusion criteria

Exclusion criteria: 1. Have a history of mental symptoms or mental illness; 2. Cognitive dysfunction (MDSE score 24 points); 3. Participated in other drug experiments within the past 3 months; 4. Severe liver and kidney dysfunction (more than 3 times the normal average); 5. Are using anti-Parkinsonian drugs.

Design outcomes

Primary

MeasureTime frame
Parkinson's Assessment Scale;

Secondary

MeasureTime frame
Constipation scale;Cognitive Function Scale;Senile Dementia Rating Scale;Schwab-England Disability Scale;Depression Scale;Parkinson's Syndrome Scale of Chinese medicine;Parkinson's Pain assessment Scale;Olfactory Argentine Questionnaire;Parkinson's sleep scale;

Countries

China

Contacts

Public ContactLi Jun

The First Affiliated Hospital of Anhui University of Chinese Medicine

18788899199@qq.com+86 18788899199

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026